Compare VLGEA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLGEA | LXRX |
|---|---|---|
| Founded | 1937 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.3M | 547.4M |
| IPO Year | 1994 | 2000 |
| Metric | VLGEA | LXRX |
|---|---|---|
| Price | $41.00 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 36.5K | ★ 2.3M |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,612,015,000.00 | $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.16 |
| P/E Ratio | $10.31 | ★ N/A |
| Revenue Growth | 0.46 | ★ 60.24 |
| 52 Week Low | $30.08 | $0.32 |
| 52 Week High | $43.35 | $1.83 |
| Indicator | VLGEA | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 50.52 |
| Support Level | $36.20 | $1.08 |
| Resistance Level | N/A | $1.65 |
| Average True Range (ATR) | 1.46 | 0.13 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 49.59 | 30.88 |
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.